Carregant...
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily comprising combination regimens implemented with a risk-adapted approach. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs(®)) lenalidomide (LEN) and pomalidomide (POM) play a central role in combinatio...
Guardat en:
| Publicat a: | Oncotarget |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Impact Journals LLC
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8310669/ https://ncbi.nlm.nih.gov/pubmed/34316334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27973 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|